Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a ...

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

Inhibiting the HIF2 protein was found to promote repair processes in a mouse model of lung injury, and may be a strategy for ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Anna Podolanczuk, M.D., M.S., discusses how biomarker testing plays a role in diagnosing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), helping to distinguish these ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...